LRP1 expression in microglia is protective during CNS autoimmunity by Tzu-Ying Chuang et al.
RESEARCH Open Access
LRP1 expression in microglia is protective
during CNS autoimmunity
Tzu-Ying Chuang1,2,3, Yong Guo4, Scott M. Seki1,3, Abagail M. Rosen1, David M. Johanson1, James W. Mandell5,
Claudia F. Lucchinetti4 and Alban Gaultier1*
Abstract
Multiple sclerosis is a devastating neurological disorder characterized by the autoimmune destruction of the central
nervous system myelin. While T cells are known orchestrators of the immune response leading to MS pathology,
the precise contribution of CNS resident and peripheral infiltrating myeloid cells is less well described. Here, we
explore the myeloid cell function of Low-density lipoprotein receptor-related protein-1 (LRP1), a scavenger receptor
involved in myelin clearance and the inflammatory response, in the context of Multiple sclerosis. Supporting its
central role in Multiple sclerosis pathology, we find that LRP1 expression is increased in Multiple sclerosis lesions in
comparison to the surrounding healthy tissue. Using two genetic mouse models, we show that deletion of LRP1 in
microglia, but not in peripheral macrophages, negatively impacts the progression of experimental autoimmune
encephalomyelitis, an animal model of Multiple sclerosis. We further show that the increased disease severity in
experimental autoimmune encephalomyelitis is not due to haplodeficiency of the Cx3cr1 locus. At the cellular level,
microglia lacking LRP1 adopt a pro-inflammatory phenotype characterized by amoeboid morphology and increased
production of the inflammatory mediator TNF-α. We also show that LRP1 functions as a robust inhibitor of NF-kB
activation in myeloid cells via a MyD88 dependent pathway, potentially explaining the increase in disease severity
observed in mice lacking LRP1 expression in microglia. Taken together, our data suggest that the function of LRP1
in microglia is to keep these cells in an anti-inflammatory and neuroprotective status during inflammatory insult,
including experimental autoimmune encephalomyelitis and potentially in Multiple sclerosis.
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Introduction
Multiple sclerosis (MS) is an inflammatory autoimmune
disease characterized by the destruction of myelin in the
central nervous system (CNS) and irreversible neurode-
generation [1]. Myelin destruction is initiated by the
myelin-reactive T cells, and is further amplified by the
inflammatory response of myeloid cells, including the
brain resident microglia and the brain infiltrating inflam-
matory macrophages [2–6].
Although it is clear that microglia and macrophages
participate in the MS pathology development, their pre-
cise functions remain extremely controversial [7]. On
one hand, microglia are proposed to be protective and
relatively immune silent in MS, when compared to
macrophages [8], while other studies demonstrate that
microglia themselves can contribute to disease initiation.
Indeed, mice with a microglia-specific deficiency in the
activation of the transcriptional master regulator of in-
flammation, NF-kB, are protected from EAE [9].
Low-density lipoprotein receptor-related protein-1
(LRP1), or CD91, is a scavenger receptor involved in the
removal of myelin debris, as well as necrotic and apop-
totic cells [10–12]. The clearance of myelin debris gener-
ated during demyelination episodes is critical for the
regenerative capacity of the CNS. Improper myelin debris
clearance by microglia has been shown to delay recovery
in a mouse model of demyelination [13]. Besides medi-
ating the removal of cellular debris, LRP1 can also
directly influence cellular signaling pathways [14]. We
have previously shown that LRP1 functions as a broad
inhibitor of NF-kB activity and inflammatory mediator
production [15]. Because inhibition of NF-kB is known
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to offer protection during experimental autoimmune
encephalomyelitis (EAE), a mouse model of MS [16–20],
placement of LRP1 at the crossroads of inflammation and
phagocytosis raises the possibility of its involvement as a
central regulator of MS pathology.
In this study, we explore the precise contribution of
LRP1 during MS, using EAE as an animal model. We
show that LRP1 protein expression is increased in the
myeloid and astrocytic compartments during active dis-
ease in MS, in comparison to the healthy CNS. To eluci-
date the role of LRP1 in myeloid cells, we induced EAE
in mice lacking LRP1 in either the peripheral or resident
myeloid cells. To our surprise, deletion of LRP1 in per-
ipheral macrophages had no effect on the disease sever-
ity, whereas in mice lacking LRP1 specifically in
microglia, disease was intensified, suggesting a protective
role for LRP1 in microglia. Further experiments revealed
that, at baseline, microglia deficient in LRP1 adopt a
pro-inflammatory phenotype and exhibit morphological
changes that parallel those observed in microglia under
inflammatory conditions. On a mechanistic level, our re-
sults suggest that the increased pathology in mice with
LRP1 deficient microglia originates from uncontrolled NF-
kB activity. Taken together, our results demonstrate that
LRP1 has a protective role in microglia and that the alter-
ation of their function can drastically impact EAE outcome.
Materials and methods
Human samples
The human pathology study was approved by the Insti-
tutional Review Board of Mayo Clinic, Rochester, MN.
Six clinically and pathologically confirmed multiple scler-
osis autopsy cases were used in this study. Formalin-fixed
paraffin-embedded 5 μm thick sections were stained for
H&E, Luxol fast blue and periodic acid Schiff (LFB/PAS),
and Bielschowsky’s silver stain for routine pathology
analysis. Immunohistochemistry was performed with
the avidin–biotin-complex method according to the
manufacturer’s instructions (Vectorlab). The following
primary antibodies are used: LRP1 (1:200, Abcam) myelin
proteolipid protein (PLP, 1:500, Serotec), myelin-associated
glycoprotein (MAG, 1:1000, Abcam), myelin oligodendro-
cyte glycoprotein (MOG, 1:1000, Abcam), CD68 (1:100,
DAKO), and glial fibrillary acidic protein (GFAP, 1:100,
DAKO). Steamed antigen retrieval with citrate buffer
(pH 6.0) was performed for LRP1, MAG, MOG, CD68,
and GFAP. The demyelinating activity in the paren-
chyma for each block was evaluated in regions derived
from the 6 cases, according to the myelin debris in
macrophages as previously described [21].
Mice
C57BL/6 mice with loxP sites flanking the LRP1 gene [22]
were crossed with Cx3cr1cre, Cx3cr1creER [9] and LysMcre
[23] mice to generate LRP1fl/flCx3cr1cre, LRP1fl/flCx3cr1creER
and LRP1fl/flLysMcre mice. To induce Cre recombinase
activity, 4 to 6-weeks old LRP1fl/flCx3cr1creER mice were
injected twice i.p. with tamoxifen (250 mg/kg in corn oil,
Sigma) 1 week apart as described in the literature [9]. For
controls, littermates carrying loxP-flanked LRP1 alleles
without Cre recombinase expression or age and sex
matched mice with Cx3cr1creER activity without loxP-
flanked LRP1 alleles, were used. All animal procedures
were approved by the University of Virginia’s Animal
Care & Use Committee.
Experimental autoimmune encephalomyelitis
EAE was induced in female mice (8 to 12 weeks) by
subcutaneous injection of MOG35-55 peptide (100 μg,
CSBio) emulsified in complete Freund’s adjuvant con-
taining Mycobacterium tuberculosis (1 mg/ml, BD). Per-
tussis toxin (200 ng, List Biologicals) was administered
i.p. on the day of and 1d after MOG immunization. For
experiments with Cx3cr1creER mice, EAE was induced
4 weeks after the tamoxifen treatment as previously de-
scribed [9]. For clinical evaluation, mice were scored
daily: 0-no clinical disease, 1-limp tail, 2-hindlimb weak-
ness, 3-hindlimb paralysis, 4-partial front limb paralysis,
5-moribund.
Antigen recall assay
Antigen recall assay was performed as previously de-
scribed [9]. Briefly, single cell suspensions were prepared
from draining inguinal lymph nodes of Cx3cr1creER
Lrp1fl/fl and control mice 7 days post immunization with
MOG35-55 peptide. Cells were treated with various con-
centrations of MOG35-55 peptide as indicated in the
manuscript for 24 h. ELISA was used to measure IFN-γ
and IL-17A production. To determine proliferation,
BrdU (10 μM, BD) was added to the culture media and
BrdU incorporation was measured 16 h after treatment
by flow cytometry.
Blood brain barrier assay
Six hours prior to the assay, mice were injected i.p. with
LPS (6 mg/kg). Heparin (20 U/mouse) was administered
i.p. and followed, 30 min later, by 2 % sodium fluores-
cein (200 μl, NaF). After another 30 min, the mice were
perfused, the meninges removed, and the brains weighed
and isolated in 50 % trichloroacetic acid overnight at 4 °
C. The tissue was finely diced and homogenized. After
centrifugation (13,000 x g, 10 min, 4 °C) and
neutralization of the acid with NaOH (5 M), 200 μl of
the clarified homogenate was plated in 96 well black/
clear bottom plates and fluorescence measured. Data is
expressed as amount of tracer per gram of tissue.
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Cell isolation from the CNS
Brain and/or spinal cords were removed and digested
in HBSS containing collagenase IV (2 mg/ml) and
DNase (20 U/ml) for 45 min at 37 °C. Cells were iso-
lated using a 30 %/70 % Percoll gradient (GE Health-
care) [24]. For adult primary microglia culture, cells
were positively selected using CD11b magnetic
microbeads (Miltenyi Biotec) after digestion. For flow
cytometry analysis, single cell suspensions were stained
with antibody against CD45 (30-F11, eBioscience),
CD11b (M1/70, eBioscience) and LRP1 (ab92544,
1:1000, Abcam). Flow cytometry analyses were per-
formed on a 10-color Beckman Coulter Gallios flow
cytometer and data were analyzed with FlowJo soft-
ware (TreeStar).
Immunofluorescence
Anesthetized mice were perfused transcardially with
PBS, followed by 4 % paraformaldehyde (PFA) prepared
in PBS. Tissues were post-fixed for at least 24 h in 4 %
PFA, and transferred to 20 % sucrose solution before
sectioning. Cryosections (40 μm) were permeabilized in
0.5 % PBS-Tween for 15 min and washed twice with
PBS. After blocking in 5 % serum in PBS for 2 h at room
temperature, sections were incubated overnight at 4 °C
with antibody against Iba1 (ab5076, 1:400, Abcam),
LRP1 (ab92544, 1:250, Abcam) and CD68 (14-0688,
1:50, eBioscience). After washing, sections were incu-
bated with secondary antibodies conjugated to Alexa488
or Alexa647 (Life Technologies). Sections were mounted
with Prolong Gold Anti-Fade Reagent containing DAPI
(Life Technologies). All sections were imaged with a
Leica TCS SP8 confocal microscope and analyzed with
ImageJ. Sholl analysis was performed as described [24].
Immunohistochemistry
Slides were deparaffinized using xylenes and an ethanol
gradient. Heat induced antigen retrieval was performed for
10 min (Sodium Citrate Buffer, pH 6). Staining for CD68,
Iba1, and LRP1 was conducted using ImmPress reagents
according to manufacturer’s instructions (Vector lab). Adja-
cent sections were stained with LFB for demyelinating pla-
ques. Histological analysis was performed by two
independent investigators, blinded to the status of LRP1.
Preparation of Bone Marrow Derived Macrophages
Mice were euthanized and dissected to retrieve femurs
and tibias. BMDM cells were cultured at 37 °C 5 % CO2
in high glucose DMEM with L-glutamine (GE Life
Sciences, SH30022) supplemented with 10 % fetal bovine
serum (Atlanta Biologicals, s12450), sodium pyruvate (Life
Technologies, 11360-070), 1x Penicillin-Streptomycin (Life
Technologies, 151490-122) and 30 % L929-conditioned
media. Fresh media was supplemented at day 4, and the
cells were replated on day 6. In some experiments, BMDM
were treated with LPS (Sigma) and other TLR ligands
(InvivoGen) as described in the text.
ELISA
ELISA analyses for IL-6 and TNF-α were performed as pre-
viously described [25]. Antibodies used were: anti-mouse
IL-6 (MP5-20 F3, Biolegend) 0.5 μg/mL; biotin anti-mouse
IL-6 (MP5-32C11, Biolegend) 1 μg/mL; anti-mouse TNF-α
(R&D systems, AF-410-NA) 0.5 μg/mL; biotin anti-mouse
TNF-α (R&D systems, BAF410) 0.25 μg/mL.
Immunoblot
Proteins were extracted in RIPA buffer supplemented
with protease inhibitor cocktail (Roche) and the phos-
phatase inhibitor sodium orthovanadate (2 mM). After
incubation for 15 min on ice, the lysates were centri-
fuged (13,000 x g, 4 °C) and protein quantified using
BCA assay. Protein samples were run on a Protean TGX
gel (Bio-Rad) and transferred to a PVDF membrane.
After blocking with 5 % milk in TBS-Tween for 1 h at
room temperature, membranes were incubated over-
night with primary antibody. After washing, membranes
were incubated with HRP conjugated secondary anti-
bodies (Pierce) for 1 h at room temperature and devel-
oped with Western Lighting Plus ECL (Perkin Elmer).
Quantitative PCR
RNA was extracted using the Isolate II Kit (Bioline)
according to manufacturer’s instructions and cDNA pre-
pared with the iScript cDNA synthesis kit (Bio-Rad).
qPCR was conducted with TaqMan primers (Applied
Biosystems) for LRP1, IL-6, TNF-α, Il-1β, and normalized
to GAPDH. Reactions were run on a PikoReal PCR system
(Thermo Fisher) with the 2x NO-ROX Sensifast Mix or
2x SYBR Sensifast Mix (Bioline).
Results
LRP1 expression is increased in MS lesions
Our previous studies demonstrated that LRP1 functions
as a receptor for myelin phagocytosis and a broad inhibi-
tor of inflammation [11, 15], two key functions linked
with MS pathogenesis. Because we observed increased
expression of LRP1 in the CNS during an animal model
of MS, experimental autoimmune encephalomyelitis
(EAE) [11], we decided to probe the potential function
of LRP1 during the human disease. We began by exam-
ining LRP1 expression in MS lesions at different stages
of demyelinating activity. In the normal appearing peri-
plaque gray matter, LRP1 was mainly detected in neu-
rons (Fig. 1a, lower row), in agreement with a previous
publication [26]. However, within the early active lesions,
characterized by the presence of CD68+ myeloid cells
containing myelin debris and GFAP+ reactive astrocytes,
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LRP1 expression was increased (Fig. 1a, upper row).
Morphological analysis suggested that LRP1 expression
was most prominent in myeloid cells (arrow) and astro-
cytes (arrowhead) in the early active lesion. The results
from a total of 6 MS autopsies are summarized in
Table 1. To confirm that myeloid cells express LRP1
within the active lesion, we performed double immuno-
fluorescence with antibodies against LRP1 and CD68.
Within the lesion, CD68+ cells are also LRP1+, while
LRP1 is not detectable within the myeloid cells outside
the lesion, confirming our immunohistochemistry results
(Fig. 1b). LRP1 immunoreactivity in myeloid cells was
also not present in inactive lesions (Table 1). Taken to-
gether, our results demonstrate that LRP1 expression in
myeloid cells and astrocytes is increased during MS
pathology.
Microglial LRP1 is protective during experimental
autoimmune encephalomyelitis
Myeloid cells involved in MS pathology are from two differ-
ent origins, the yolk sac derived CNS resident microglia
[27] and the peripheral infiltrating macrophages. To ex-
plore the function of myeloid LRP1, we used the well-
accepted animal model of MS, EAE, in two different mice
strains lacking LRP1 either in peripheral myeloid cells or in
microglia. To study the function of LRP1 in peripheral
myeloid cells, we induced EAE in LRP1 deleted LysMcre-
Lrp1fl/fl or the control Lrp1fl/fl mice with the myelin oligo-
dendrocyte glycoprotein (MOG35-55) peptide and scored
the mice daily. While LysM is highly expressed in periph-
eral myeloid inflammatory cells, LysM expression in micro-
glia is variable [9, 28]. Using LysMcre-Lrp1fl/fl mice [29], we
observed complete deletion of LRP1 in bone marrow de-
rived macrophages (BMDM), while we observed little to no
decrease in basal microglial LRP1 expression, as demon-
strated by flow cytometry (Fig. 2a). Given that we have pre-
viously shown that macrophage LRP1 functions as an
inhibitor of inflammation, we were surprised to find that
deletion of LRP1 in peripheral myeloid cells in LysMcre-
Lrp1fl/fl mice had no effect on the clinical score or incidence
of EAE (Fig. 2b-c). Clinical scores were also similar when
EA
LRP1GFAPCD68PLPPLP
CD68 LRP1 DAPI Merge
PPGMCDM
LFB
1 2 3 4
Fig. 1 LRP1 expression is increased in MS lesions. a Immunohistochemistry on consecutive sections from an early active (EA) MS lesion (upper row)
shows: (1) myelin (PLP) laden macrophages consistent with ongoing demyelinating activity, (2) abundant macrophage infiltration (CD68), (3)
hypertrophic reactive astrocytes indicating gliosis (GFAP), and (4) LRP1 immunoreactivity present on both astrocytes (arrowhead) and macrophages
(arrow and inset). In contrast, the periplaque gray matter (PPGM, lower row) shows: (1) normal appearing myelin (PLP), (2) limited microglial reactivity
(CD68), (3) astrocytes with regular size and morphology (GFAP), and (4) limited LRP1 immunoreactivity. (Scale bars = 20 μm). b Luxol Fast Blue
histology (LFB) and immunofluorescence for CD68 and LRP1 shows that myeloid cells express LRP1 within the lesion (Scale bar = 100 μm)
Table 1 LRP1 expression in MS: 6 clinical and pathologically
confirmed multiple sclerosis autopsy samples were analyzed
Lesion stage from MS
autopsy
LRP1 expression in the Lesion
Myeloid Cells Neurons Astrocytes
Early Active 100 % (2/2) NAa (0/2) 100 % (2/2)
Late Active 0 % (0/1) NAa (0/1) 100 % (1/1)
Periplaque White Matter 0 % (0/5) NAa (0/5) 100 % (5/5)
Non-Affected White Matter 0 % (0/5) NAa (0/5) 100 % (5/5)
Chronic Demyelination 0 % (0/4) 100 % (4/4) 100 % (4/4)
Non-Affected Gray Matter 0 % (0/5) 100 % (5/5) 100 % (5/5)
Formalin-fixed paraffin-embedded 5 μm thick sections were stained for H&E,
Luxol fast blue and periodic acid Schiff (LFB/PAS), and Bielschowsky’s silver
stain for routine pathology analysis. For cellular analysis, slides were stained
for LRP1, myeloid marker CD68, and reactive astrocyte marker GFAP. Neurons
were not detected in white matter
aNA not applicable
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the amount of mycobacterium was increased to induce a
stronger EAE disease course (Additional file 1: Figure S1)
[30].
Next, we generated a new mouse strain to study the
role of LRP1 in microglia during EAE. The Lrp1fl/fl strain
[22] was crossed to the recently developed Cx3cr1creER
strain [31] to generate Cx3cr1creER-Lrp1fl/fl animals. Be-
cause CX3CR1 is expressed in microglia and monocytes
[9], tamoxifen treatment initially leads to the deletion of
LRP1 in both cell types. However, the pool of circulating
monocytes that can give rise to macrophages during in-
flammation is continuously renewed by progenitors from
the bone marrow, while the long-lived brain resident
microglia are not replenished and remain LRP1 deleted [2,
9]. Indeed, 1 month after the administration of tamoxifen,
we could still detect deletion of LRP1 in microglia, while
LRP1 expression in bone marrow derived macrophages was
comparable to control cells (Fig. 2d). EAE was induced by
immunization with MOG35-55 peptide. LRP1 deletion in
microglia results in a significant increase in clinical scores
and overall incidence of EAE (Fig. 2e-f). Difference in the
clinical score was not due to CX3CR1 haplodeficiency, as
induction of EAE in animals that were not treated with
tamoxifen showed no significant difference between groups
(Additional file 1: Figure S2). Our results suggest that LRP1
expression in microglia has a protective role in EAE, signifi-
cantly reducing the disease severity.
Demyelination and peripheral immune cell recruitment are
elevated in mice lacking LRP1 in microglia
To explore the pathological conditions leading to an
exacerbated disease course in EAE mice lacking LRP1
expression in microglia, we performed histological analysis
of the spinal cord during the chronic phase of the disease
(day 30). Myelin staining of the spinal cord sections with
Luxol Fast Blue revealed that Cx3cr1creER-Lrp1fl/fl mice have
significantly more white matter demyelination than the
control group (Fig. 3a). This difference was statistically sig-
nificant at all of the spinal cord levels that were examined:
Lumbar, thoracic and cervical levels. Immune cells are re-
sponsible for driving demyelination during EAE. To explore
if LRP1 deficiency in microglia could alter immune cell
numbers, we performed flow cytometry and immunohisto-
chemical analysis of the spinal cords at the onset of disease
(day 15). Histologically, we find increased numbers of CD3
+ T cells and Iba1+ cells in the Cx3cr1creER-Lrp1fl/fl mice at
disease onset (Fig. 3b-c), especially evident in the dense
infiltrates in the white matter of the spinal cord. By flow
cytometry (Additional file 1: Figure S3), our results reveal
that the number of T cells and peripheral myeloid
(CD11bhiCD45hi) cells was significantly increased in
animals lacking LRP1 (Fig. 3d-e). Finally, there was a trend
towards increased numbers of microglia (CD11bmidCD45hi)
and B cells (CD19+) (Fig. 3f-g). Taken together, our results
show that mice lacking LRP1 in microglia had increased
EAE susceptibility that is associated with robust demyelin-
ation and increased infiltration of immune cells from the
innate and adaptive arms of the immune system.
Lymphocyte activation is not affected in the absence of
LRP1
LRP1 is a multifunctional receptor with roles that could
impact EAE progression at different levels [14]. As LRP1
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Days post MOG injection
Fig. 2 Deletion of LRP1 from microglia, but not from peripheral myeloid cells, exacerbates EAE progression. a LRP1 expression was determined
by flow cytometry on microglia and BMDM isolated from LysMcre-Lrp1fl/fl and Lrp1fl/fl mice. b Clinical scores and c incidence of LysMcre-Lrp1fl/fl and
Lrp1fl/fl mice (n = 7–9 for each group, representative of 3 independent experiments). d LRP1 expression was determined by flow cytometry on
microglia and BMDM isolated from Cx3cr1creER-Lrp1fl/fl and Lrp1fl/fl mice. e Clinical scores and f incidence of Cx3cr1creER-Lrp1fl/fl and Lrp1fl/fl mice
(n = 6–10 for each group, representative of 3 independent experiments.). 2-way ANOVA was used for the mean clinical score and the log-rank
(Mantle-Cox) test was used for incidence. ***p < 0.001, mean ± s.e.m
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be expressed in subsets of antigen presenting cells
(APC) in the periphery [33], we investigated the antigen
recall response of inguinal lymph node T cells in the
Cx3cr1creER-Lrp1fl/fl mice 7 days after immunization.
Treatment with MOG35-55 peptide did not reveal any
significant differences in T cell production of IFN-γ and
IL-17A, as determined by ELISA (Fig. 4a-b). Further-
more, T cell proliferation measured by BrdU incorpor-
ation was also comparable to control cells (Fig. 4c).
Taken together, these data suggest that increased disease
severity in EAE for Cx3cr1creER-Lrp1fl/fl mice is not
linked to impaired antigen presentation in the periphery.
Function of the blood brain barrier is intact in mice lacking
microglial LRP1
Blood Brain Barrier (BBB) permeability disruption is an
essential event in providing access to peripheral lympho-
cyte infiltration into the CNS during EAE [34], and
microglia are known to modulate the function of the
BBB [35]. To investigate if LRP1 deletion in microglia
can impact BBB permeability, we induced microgliosis in
Cx3cr1creER-Lrp1fl/fl and control mice by injecting LPS,
as previously described [36]. LPS administration leads to
increased extravasation of fluorescein in comparison to
the basal level, as expected [35]. However, BBB perme-
ability was not affected by the status of LRP1 expression
in microglia (Fig. 4d). These results suggest that LRP1
function in microglia is likely not critical for the main-
tenance of the BBB function.
Microglial morphology is altered by LRP1 deficiency
Since our results suggested that T cell and BBB function
is normal in the absence of LRP1 expression in CX3CR1
positive cells, we hypothesized that the increased disease
severity is due to an intrinsic function of LRP1 in micro-
glia. Therefore, we analyzed the morphology of microglia
in the cortex of Cx3cr1creER-Lrp1fl/fl and control mice at
both the resting state, and after inducing microgliosis via
peripheral administration of LPS for 4 consecutive days,
as described [37]. LRP1 status in microglia did not affect
the weight of the animals injected with LPS (Additional
file 1: Figure S4). We chose this model instead of EAE
because of the lack of good markers to differentiate
microglia from peripheral myeloid cells by immuno-
chemistry. Because this model of neuroinflammation
lacks recruitment of peripheral immune cells, a more fo-
cused analysis of microglia morphology is possible [37].
Brain sections were stained with Iba1 specific antibody
and microglial ramifications were quantified by Sholl
analysis in the cortex (Fig. 5a-b). In the healthy control
mice, microglia appear thin and ramified (Fig. 5b, grey
curve) [37]. Surprisingly, microglia lacking LRP1 expres-
sion appeared more amoeboid than the control cells at
baseline, with a denser cell body and thickened proximal
dendrites (Fig. 5b, grey vs. orange curves). Whereas LPS
administration in control mice leads to the transition of
microglial morphology into the bushy and thickened
appearance (Fig. 5b, grey vs black curves), LPS had no
effect on the appearance and branching of LRP1 defi-






















































































































Fig. 3 Microglial LRP1 deficient mice have increased demyelination
and numbers of immune cells in the CNS during EAE. Spinal cord
sections of Cx3cr1creER-Lrp1fl/fl and Lrp1fl/fl mice were stained with
Luxol Fast Blue a at day 30 (n = 4 for each group), and CD3 b (n = 4
for each group) and Iba1 c (n = 4 for each group) at day 15. Cells
were manually quantified. For LFB, 2 sections per spinal cord level
are plotted from each animal. For CD3 and Iba1, each point
represents one animal. Immune cells were isolated by percoll
gradient from spinal cords of Cx3cr1creER-Lrp1fl/fl and Lrp1fl/fl mice.
Number of d peripheral myeloid cells (CD11bhiCD45hi), e T cells
(TCRβ+) cells, f microglia (CD11bhiCD45mid), and g B cells (CD19+)
were determined by flow cytometry analysis (n = 3 for each group).
*p < 0.05, **p < 0.01; Student’s t-test, mean ± s.e.m
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administration significantly increased the soma size of
control microglia, but not the microglia lacking LRP1
expression (Fig. 5c). Quantification of the area covered
by Iba1+ cells confirms that LRP1 deletion leads to
microglial hypertrophy. The morphology of these LRP1
deficient microglia are similar in appearance to the
microglia observed in LPS treated control mice (Fig. 5d).
These morphological changes were not associated with
an overall change in numbers of microglia (Fig. 5e). Our
results suggest that the removal of LRP1 alters microglial
morphology in a manner similar to treatment with LPS,
a potent neuroinflammatory stimulus.
Microglia lacking LRP1 have a pro-inflammatory signature
One potential mechanism by which microglia lacking
LRP1 could affect EAE pathology is through increased
production of inflammatory mediators, as LRP1 func-
tions as an inhibitor of the inflammatory response [15].
To test the inflammatory response in LRP1 deficient
microglia, we isolated primary microglia from Lrp1fl/fl
and Cx3cr1cre-Lrp1fl/fl mice and analyzed their produc-
tion of TNF-α, a key cytokine involved in EAE pathology
[38]. LPS stimulation of LRP1 deficient microglia results
in increased production of TNF-α at both the transcript
(Fig. 6a) and the protein level (Fig. 6b). This increase in
TNF-α is comparable to the one observed in primary
cultures of BMDM (Fig. 6c-d), as we have previously
reported [15]. In BMDM, the pro-inflammatory signa-
ture generated by the lack of LRP1 also extends to IL-1β
and IL-6 production (Fig. 6e-f ). More importantly, this
pro-inflammatory signature was also observed in the
CNS of Cx3cr1creER-Lrp1fl/fl mice at the disease onset, as
detected by qPCR (Fig. 6g). Taken together, our results
demonstrate that, in the absence of LRP1, microglia
adopt a pro-inflammatory phenotype that could contribute
to increased pathology in EAE.
LRP1 blocks NF-kB function
Production of cytokines, like TNF-α, IL-6 and IL-1β, is
tightly controlled via signaling through NF-kB, a tran-
scriptional master regulator of the inflammatory re-
sponse [39]. Indeed, recent studies have demonstrated
that blocking NF-kB activation specifically in microglia
is sufficient to offer protection during EAE [9]. Previous
reports have highlighted the fact that LRP1 can act as an
inhibitor of inflammation through regulation of NF-kB
activity [15]. We therefore hypothesized that LRP1 may
function as a regulator of NF-kB mediated inflammatory
response in microglia. Because the inflammatory medi-
ator production appears similar in cultured microglia
and BMDM lacking LRP1 (Fig. 6), we began by treating
Lrp1fl/fl and Cx3cr1cre-Lrp1fl/fl BMDM with LPS and col-
lecting protein extracts at several time points after


































































Fig. 4 Immune response and blood brain barrier permeability are not altered in microglial LRP1 deficient mice. Seven days after MOG
immunization, draining lymph nodes were isolated from Cx3cr1creER-Lrp1fl/fl and Lrp1fl/fl mice and incubated with MOG. a-b IFN-γ and IL-17A pro-
duction were determined by ELISA after 24 h. c BrdU incorporation by T cells was determined after 16 h by flow cytometry (n = 3–5 mice were
used per group per experiment). Statistical analysis was performed with 2-way ANOVA. d The amount of fluorescein present in brains following
LPS treatment (6 mg/kg) was measured in Cx3cr1creER-Lrp1fl/fl and Lrp1fl/fl mice to assess function of the blood brain barrier. Statistical analysis was
performed with Student’s t-Test; means ± SEM
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phosphorylation status of the NF-kB subunit p65. As is
shown in Fig. 7a, LPS stimulated LRP1 deficient macro-
phages have increased levels of phosphorylated p65 (p-
p65), in comparison to control cells. LPS is the only Toll-
like receptor (TLR) ligand known to activate two different
signaling pathways: the MyD88 and the TRIF pathway
[39]. To elucidate which arm of the signaling cascade is
regulated by LRP1, we treated BMDM with a panel of
TLR ligands that are associated with the TRIF (TLR3 lig-
and: PolyI:C), or the MyD88 adaptor response (TLR1 and
2 ligand: Pam3CSK4; TLR5 ligand: FLA-ST; TLR6 ligand:
FSL-1; TLR9 ligand: ODN1826) [40]. BMDM were treated
for 3 h and IL-6 expression was determined by qPCR
analysis. IL-6 expression was increased in LRP1 defi-
cient macrophages when the MyD88 pathway was en-
gaged by the activation of TLR 1, 2, 4, 5, 6, and 9.
On the contrary, TLR3-mediated production of IL-6
was not affected by the status of LRP1, showing that
LRP1 may inhibit the NF-kB signaling pathway in a
MyD88, but not TRIF dependent manner (Fig. 7b).
Together, these results suggest that LRP1 functions as
a regulator of NF-kB activity through modulation of
the MyD88 dependent arm of the inflammatory re-
sponse. This function of LRP1 might explain why its






















































































































Fig. 5 LRP1 deficient microglia have an amoeboid morphology. Cx3cr1creER-Lrp1fl/fl and Lrp1fl/fl mice were injected daily with LPS (1 mg/kg) for 4
consecutive days. Brain sections were stained with Iba1 antibody, imaged by confocal microscopy and analyzed with ImageJ. a Representative
images of microglia and b corresponding Sholl analyses. *p < 0.05; **p < 0.01; ***p < 0.001, 2-way ANOVA. (Scale bar = 60 μm). c Soma size of the
microglia. 10 microglia per animal were quantified for each experimental group. **p < 0.01, Student’s t-test. d Quantification of area covered by
Iba1+ microglia per image. *p < 0.05, Student’s t-test. e Numbers of microglia per unit area (n = 3–4 mice per condition). Values represent mean
± s.e.m
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Discussion
In this study, we explore the function of LRP1 expres-
sion in myeloid cells during MS using the mouse model
EAE. To begin, we have made the novel observation that
LRP1 protein expression is significantly increased in hu-
man MS lesions, compared to normal appearing brain
tissue. The cellular compartments involved in the
increase of LRP1 immunoreactivity included the
myeloid cells and astrocytes. This observation is in
agreement with our previous work showing that LRP1
expression is upregulated during EAE [11] and the
work of Hendrickx et al., showing that LRP1 tran-
script is increased at the rim of MS lesions [41]. The
LRP1 expression increase by glia is not limited to
MS, as previous work has demonstrated a similar pat-
tern during CNS injury and neoplasia [42]. Therefore,
although our study centered on LRP1 function in
myeloid cells, future studies will be needed to under-
stand the role of LRP1 in astrocytes.
Here, we have explored the contribution of LRP1 ex-
pression during EAE in two distinct myeloid cell popula-
tions: Peripheral macrophages and microglia. To our
surprise, we have discovered that LRP1 deletion in per-
ipheral macrophages had no detectable impact on EAE
progression. This result is in stark contrast with the con-
sequence of LRP1 deletion in microglia, which leads to a
significant worsening of disease progression. We, and
others, have previously demonstrated that macrophages
lacking LRP1 expression display a pro-inflammatory
phenotype in vitro, characterized by increased produc-
tion of inflammatory mediators, chemokines and an M1-
type macrophage skewing [15, 43, 44], suggesting that
the removal of LRP1 in macrophages could impact the
progression of EAE in a detrimental manner. Therefore,
we were surprised to find that LRP1 deletion in LysMcre-
Lrp1fl/fl mice did not result in increased disease severity
in two separate EAE protocols (varying in the amount of













































































































Fig. 6 LRP1 deficient myeloid cells have a pro-inflammatory signature. Microglia (MG) and BMDM (MΦ) isolated from Cx3cr1cre-Lrp1fl/fl and Lrp1fl/fl
mice were treated with LPS (1 μg/mL) for 3 h (qPCR) or 24 h (ELISA). TNF-α expression in microglia was determined by qPCR (a) and ELISA (b).
TNF-α expression in macrophages was determined by qPCR (c) and ELISA (d). Expression of IL-1β (e) and IL-6 (f) in macrophages was determined
by qPCR. g Transcript expression of IL-1β, IL-6, and TNF-α from the CNS of Cx3cr1creER-Lrp1fl/fl and Lrp1fl/fl mice at the peak of EAE. 5, **p < 0.01,
***p < 0.001; Student’s t-test
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Freund’s adjuvant). One potential explanation for these
observations is that the peripheral immune cells are
primed for a powerful inflammatory response prior to
their entry into the CNS, and the removal of LRP1 does
not alter their function in the diseased tissue. Future
studies are necessary to distinguish whether LRP1 dele-
tion in peripheral myeloid cells alters their function
under homeostatic conditions.
On the contrary, ablation of LRP1 in microglia had a
significant impact on EAE disease severity and progres-
sion. Microglia are the resident myeloid cells of the CNS
and their function in EAE remains actively debated;
while some studies suggest that they actively participate
in disease initiation and peripheral immune cell recruit-
ment [9, 45], others show that microglia remain rela-
tively inert during EAE [8]. Microglia have also been
reported to express higher levels of the LRP1 transcript,
compared to the peripheral macrophages, in both EAE
and the homeostatic conditions [46, 47]. Therefore, we
propose that microglia lacking LRP1 acquire an inflam-
matory phenotype that leads to disease exacerbation in
EAE. In agreement with this hypothesis are the observa-
tions that LRP1 deficient microglia appear amoeboid
and hypertrophic, even in the absence of ongoing dis-
ease. The transition from a ramified morphology to a
more compact appearance by microglia has been de-
scribed by many groups as an hallmark of inflammation
[37, 48]. The fact that microglia appear activated in the
healthy brain does suggest that they are primed to pro-
duce a more robust inflammatory response. Indeed,
microglia lacking LRP1 secrete more TNF-α after LPS
stimulation in vitro, a key cytokine involved in EAE
pathology [38].
On a mechanistic level, we propose that LRP1 is an in-
hibitor of NF-kB signaling in myeloid cells, in agreement
with our previous studies [15, 44]. Here, for the first
time, we show that LRP1 only influences the MyD88
arm of TLR signaling, suggesting that LRP1 only has an
effect on the extracellular TLR ligands [40]. Further
studies are needed to understand if the role of LRP1 as
an NF-kB inhibitor intersects with LRP1 function in the
removal of myelin debris. Indeed, the function of LRP1
in the removal of degraded myelin and dying cells could
be critical in maintaining CNS homeostasis under nor-
mal physiological conditions, as well as in removing the
degenerating oligodendrocytes during MS [10, 11].
Proper clearance of the myelin debris is critical for brain
function, as the release of degenerated myelin could fur-
ther propagate inflammation and damage the CNS. Fur-
thermore, myelin-laden macrophages isolated from the
brain are known to have decreased inflammatory re-
sponses, when compared to macrophages that have not
engulfed myelin [49]. The receptors and mechanisms
that initiate the anti-inflammatory response to apoptotic
cell or myelin engulfment are still poorly understood
[50]. Further studies will be needed to understand if
LRP1 mediated signaling in microglia can initiate an
anti-inflammatory response, thereby exerting protection
in EAE and, perhaps, MS.
Conclusion
In conclusion, we demonstrated that LRP1 expression is
significantly upregulated by myeloid cells in active MS
lesions. To study the role of LRP1 in myeloid cells, we
induced EAE in mice lacking LRP1 in microglia or in
macrophages and showed that only microglial LRP1 was
protective, as animal lacking LRP1 in this compartment
experienced a worse clinical outcome. At the mechanis-
tic level, our study demonstrates that LRP1 regulates in-
flammation by inhibiting NF-kB, a master regulator of
inflammation, via a MyD88 dependent pathway.
Additional file
Additional file 1: Figure S1. Higher dose of mycobacterium does not
affect EAE progression in LysMCre-Lrp1fl/fl and Lrp1fl/fl mice. Figure S2.
CX3CR1 haplodeficiency does not affect EAE progression. EAE was
induced in Cx3cr1creER-Lrp1fl/fl and Lrp1fl/fl mice without tamoxifen
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Fig. 7 LRP1 is an inhibitor of NF-kB through the MyD88 pathway. a
Macrophages isolated from Cx3cr1cre-Lrp1fl/fl (LRP1-) and Lrp1fl/
fl (LRP1+) mice were treated with LPS (1 μg/ml) and the expression
of p-p65, p65, LRP1 and actin were determined by immunoblot.
Representative of 3 independent experiments). b LRP1+ and LRP1-
macrophages were treated with TLR ligands and expression of IL-6
was determined by qPCR analysis. *p < 0.05; Student’s
t-test, mean ± s.e.m
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macrophages, microglia and lymphocytes (Figs. 2 and 3). Figure S4. LRP1
deficiency in microglia does not alter weight loss after LPS treatment.
Cx3cr1creER-Lrp1fl/fl and Lrp1fl/fl mice were injected with LPS (1 mg/kg) for 4
consecutive days and the weight of the animals was monitored daily.
(PDF 1368 kb)
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